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Abstract. The opioid pentapeptide leucine-enkephalinamide and eleven of its analogues have 
been synthesised by the solid phase technique employing mostly 9-fluoroenylmethyloxycar- 
bonyl amino acid active esters in the presence of 1-hydroxybenzotriazole. Both the 
conventional chloromethylated copolystyrene-2% divinylbenzene resin as well as
p-alkoxybenzyl alcohol resin were employed and it was observed that yields were uniformly 
better with the latter resin. The analogues were made by affecting single or multiple 
replacements of amino acids involving positions 1,2 and 5. Some of the analogues were found 
to be more potent than morphine in the guinea pig ileum assay.
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Introduction 
 
The importance of Tyr1 in the opioid pentapeptides leucine- and methionine- 
enkephalins, Tyr1-Gly2-Gly3-Phe4-Leu/Met5, has been well recognised (Morley, 
1980). Its replacement by other amino acids generally leads to loss of biological activity. 
Further, the shortening of the side chain which happens when it is replaced by L-p- 
hydroxyphenylglycine resulted in virtual loss of activity (Dutta et al., 1977). The 
consequences of replacing Tyr1 by D-p-hydroxyphenylglycine have now been in- 
vestigated. Substitution of Gly2 in the enkephalins by D-amino acids generally leads to 
enhanced activity (Morley, 1980); hence, 5 analogues with D-amino acids in this 
position have been made by us. In two other analogues D-amino acids replace both 
Tyr1 and Gly2. Three more analogues have been prepared by replacement of Gly2 and 
Leu/Met5. 
 
 
Experimental 
 
All the amino acids used, except glycine, are of L-configuration unless otherwise 
specified. Melting points were determined using Leitz-Wetzlar melting point apparatus 
 
 
Abbreviations used: Fmoc, 9-Fluorenylmethyloxycarbonyl; OTcp, trichlorophenyl ester; HOBt, 1-hydroxy- 
benzotriazole; D-Gly(p-OH-phenyl), p-hydroxyphenylglycine; Nle, norleucine; AcOH, acetic acid; NEt3, 
triethylamine; Et2 NH, diethylamine; DMF, dimethylformamide. 
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and are uncorrected. Thin layer chromatography was carried out on silica gel G plates 
using the solvent system, chloroform: methanol: acetic acid (40:5:5), and the Rf value 
is designated as Rf(CMA).Fmoc-amino acids were prepared by the method of Chang et 
al. (1980). Fmoc-amino acid active esters were prepared by methods similar to those 
used for the corresponding tert-butyloxycarbonyl amino acids. The coupling and 
deprotection steps during the synthesis were monitored by Kaiser's test (Kaiser et al., 
1970). 
 
 
Fmoc -Leu-OCH2-C6H4-OCH2-C6H4-resin 
 
Fmoc-Leu (7·06g, 20 mmol) was reacted with p-alkoxybenzyl alcohol resin (12 g, 
prewashed with dichloromethane) using dicyclohexylcarbodiimide (4·12 g, 20 mmol) 
and p-dimethylaminopyridine (2·45 g, 20 mmol) in 4 : 1 dichloromethane/dimethyl
formamide (240 ml) according to Chang's procedure (Chang et al., 1980) to afford the 
title peptide resin; yield 13·5 g; leucine content: 0·41 mmol/g of resin (Meienhofer et al., 
1979) 
 
 
Fmoc-Phe-Leu-OCH2-C6H4-OCH2-C6H4-resin 
 
Fmoc-Leu-OCH2-C6H4-OCH2-C6H4-Resin (13·5 g) was subjected to the following 
cycles using 120 ml solvent for each operation. 
CH2Cl2 Wash, 3×2 min. 
Deblocking with 55% piperdine in CH2Cl2, 1 × 40 min. 
CH2Cl2 wash, 3 × 2 min. 
DMF wash, 2 ×2 min. 
Dioxane: Water (2:1) wash, 3 × 5 min. 
DMF wash, 2 × 2 min. 
CH2Cl2 wash, 2×2 min. 
DMF wash, 2×2 min. 
Coupling with Fmoc-Phe-OTcp (3 equiv.)/HOBt (1 equiv.) in DMF (45 ml), 60 min. 
DMF wash, 2×2 min. 
Isopropanol wash, 2×2 min. 
 
 
Fmoc-Gly-Phe-Leu-OCH2-C6H4-OCH2-C6H4-resin 
 
The procedure described in the previous preparation was repeated to introduce the 
glycine unit using Fmoc-Gly-OTcp (7·9 g, 16·6 mmol) and 1-hydroxybenzotriazole 
(0·74 g, 5·5 mmol) in DMF (45 ml). 
 
BOC-Tyr-Gly-Gly-Phe-Leu-OCH2-C6H4-OCH2-C6H4-Resin (I), BOC-Tyr-D-Ala-
Gly-Phe-Leu-OCH2-C6H 4-OCH2-C6H4-Resin (II), BOC-Tyr-D-Val-Gly-Phe-Leu-
OCH2-C6H4-OCH2-C6H4-Resin (III), BOC-D-Gly(p-OH-phenyl)-Gly-Gly-Phe- 
Leu-OCH2-C6H4-OCH2-C6H4-Resin (IV), BOC-D-Gly(p-OH-phenyl)-D-Ala-Gly- 
Phe-Leu-OCH2-C6H4-OCH2-C6H4-Resin (V), and BOC-D-Gly(p-OH-phenyl)-D- 
Val-Gly-Phe-Leu-OCH2-C6H4-OCH2-C6H4-Resin (VI) 
 
Using portions of the tripeptide resin, Fmoc-Gly-Phe-Leu-OCH2-C6H4-OCH2- 
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C6H4-Resin, and performing the same cycle of operations that was employed for the 
introduction of Gly and Phe but using appropriate amino acid active esters, the 
protected peptide resins (I to VI) were obtained.
 
 
BOC-Leu-OCH2-C6H4 -Resin and BOC-Nle-OCH2-C6H4-resin 
 
To a suspension of Merrifield resin (2 g) in ethanol (8 ml), BOC-Leu (or BOC-Nle) 
(0·65 g, 2·8 mmol) and triethylamine (0·392 ml, 2·8 mmol) were added and the mixture 
was stirred slowly at 90° under anhydrous conditions for 24 h. The esterified resin was 
collected and washed successively with ethanol, water, ethanol, dichloromethane and 
methanol and dried over P2O5 in vacuo. Yield 2·35 g. The leucine (and norleucine) 
content on the resin was estimated to be 0·45mmol/g of resin (Stewart and Young, 
1969). 
 
BOC-Tyr-D-Gly(p-OH-phenyl)-Gly-Phe-Leu-OCH2-C6H4-Resin (VII), BOC-Tyr- 
D-Ser-Gly-Phe-Leu-OCH2-C6H4-Resin (VIII), BOC-Tyr-D-Phe-Gly-Phe-Leu- 
OCH2-C6H4-Resin (IX), BOC-Tyr-D-Ser-Gly-Phe-Nle-OCH2-C6H4-Resin (X), 
BOC-Tyr-D-Phe-Gly-Phe-Nle-OCH2-C6H4-Resin (XI), and BOC-Tyr-D-Met-Gly- 
Phe-Nle-OCH2-C6H4-Resin (XII) 
 
BOC-Leu-OCH2-C6H4-Resin and BOC-Nle-OCH2-C6H4-Resin were taken in 
separate solid phase vessels and peptide synthesis was carried out using a manual 
procedure. All washings and reactions were carried out using 10–12 ml portions of 
solvents per gram of resin. Each cycle of the synthesis consisted of the following 
operations. 
CH2Cl2 wash, 2×2min. 
DMF wash, 2 × 2 min. 
Deprotection with 50% diethylamine in DMF 1 × 120 min. (The BOC group of the 
first amino acid was deprotected using 1Ν HCl/AcOH for 30 min., with AcOH 
(3 × 2 min.) wash preceding and succeeding the deprotection step, and neutralization 
with 10% NEt3 -DMF for l0min.)
DMF wash, 2 × 2 min. 
Dioxane: Water (2:1) wash, 2× 5 min. 
DMF wash, 3×2 min. 
CH2Cl2 wash, 3×2 min. 
DMF wash, 2×2 min. 
Coupling with 3 equiv. of Fmoc-amino acid active ester/1 equiv. HOBt in DMF. 
[Fmoc-D-Ser (3 equiv.) was added in the presence of DCC (2 equiv.)/HOBt 
(1 equiv.) in DMF. The last amino acid Tyr was incorporated using BOC-Tyr-OTcp 
(3 equiv.)/HOBt (1 equiv.)] 
DMK wash, 
Isopropanol wash. three times successively 
CH2Cl2 wash, 2 min. each. 
 
After the incorporation of the third amino acid, each of the peptide resins (Fmoc- 
Gly-Phe-Leu-OCH2-C6H4-Resin and Fmoc-Gly-Phe-Nle-OCH2-C6H4-Resin) was 
dried and divided into 3 equal parts and the synthesis was continued to incorporate the 
last two amino acids. 
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The time required for the completion of coupling of each amino acid is given below. 
 
 
BOC-Tyr-Gly-Gly-Phe-Leu-NH2 (XIII), BOC-Tyr-D-Ala-Gly-Phe-Leu-NH2 (XIV), 
BOC-Tyr-D-Val-Gly-Phe-Leu-NH2 (XV), BOC-D-Gly(p-OH-phenyl)-Gly-Gly-Phe- 
Leu-NH2 (XVI), BOC-D-Gly-(p-OH-phenyl)-D-Ala-Gly-Phe-Leu-NH2 (XVII), 
BOC-D-Gly(p-OH-phenyl)-D-Val-Gly-Phe-Leu-NH2 (XVIII), BOC-Tyr-D-Gly(p- 
OH-phenyl)-Gly-Phe-Leu-NH2 (XIX), BOC-Tyr-D-Ser-Gly-Phe-Leu-NH, (XX), 
BOC-Tyr-D-Phe-Gly-Phe-Leu-NH2 (XXI), BOC-Tyr-D-Ser-Gly-Phe-Nle-NH2 
(XXII), BOC-Tyr-D-Phe-Gly-Phe-Nle-NH2 (XXIII) and BOC-Tyr-D-Met-Gly-Phe- 
Nle-NH2 (XXIV) 
 
Each of the protected peptide resins (XIII to XXIV) was allowed to swell in absolute 
methanol (50 ml/g of resin) for 2 h. The suspension was cooled to –10° and saturated 
with dry ammonia with stirring. The mixture was stirred for 3 h at –10° and 72 h at 0°. 
The resin was filtered off and washed with hot methanol. The combined filtrate was 
evaporated to dryness. The residue was again evaporated with additional amounts of 
methanol to expel ammonia completely. The residue was purified using ethyl acetate 
and methanol/ether. The yields of the title peptides are given in the scheme mentioned 
later. 
 
Tyr-Gly-Gly-Phe-Leu-NH2 (XXV), Tyr-D-Ala-Gly-Phe-Leu-NH2 (XXVI), Tyr-D- 
Val-Gly-Phe-Leu-NH2 (XXVII), D-Gly(p-OH-phenyl)-Gly-Gly-Phe-Leu-NH2 
(XXVIII), D-Gly(p-OH-phenyl)-D-Ala-Gly-Phe-Leu-NH2 (XXIX), D-Gly(p-OH- 
phenyl)-D-Val-Gly-Phe-Leu-NH2 (XXX), Tyr-D-Gly(p-OH-phenyl)-Gly-Phe-Leu- 
NH2 (XXXI), Tyr-D-Ser-Gly-Phe-Leu-NH2 (XXXII), Tyr-D-Phe-Gly-Phe-Leu-NH2 
(XXXIII), Tyr-D-Ser-Gly-Phe-Nle-NH2 (XXXIV), Tyr-D-Phe-Gly-Phe-Nle-NH2 
(XXXV) and Tyr-D-Met-Gly-Phe-Nle-NH2 (XXXVI) 
 
For the removal of BOC group, each of the protected peptides (XIII to XVIII) was 
dissolved in trifluoroacetic acid (3·0 ml per 100 mg of peptide) and allowed to stand at 
room temperature for 40 min. Each of the other protected peptides (XIX to XXIV) was 
dissolved in 98 % formic acid (2·0 ml per l00 mg peptide) in the presence of anisole
(10 %, v/v) and allowed to stand at room temperature for 3 h. The acid was removed in 
vacuo. The residue was dissolved in anhydrous methanol and precipitated with dry 
ether. The hygroscopic solid thus obtained was dissolved in methanol (50 ml for 100 mg 
peptide) and treated with Amberlite IRA-400 till the solution attained a pH of 7·5. The 
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resin was filtered off and washed with methanol. The combined filtrate was 
concentrated under reduced pressure and dried in vacuo over P2O5 to afford the 
peptides (XXIV to XXXVI), whose yields are shown in the scheme given later.
The physical constants of the peptides are listed below. (Amino acid analysis and 
elemental analysis (C, Η and N) of the peptides gave satisfactory results).
 
Results 
 
For the synthesis of these analogues the solid phase technique (Merrified, 1963) was 
employed using either the conventional Merrifield resin (chloromethylated 
copolystyrene-2 % divinylbenzene) or p-alkoxybenzyl alcohol resin (Wang, 1973). For 
building the peptide chain Fmoc-amino acid active esters were generally employed in 
the presence of 1-hydroxybenzotriazole (Khan and Sivanandaiah, 1976; Sivanandaiah 
and Gurusiddappa, 1981). However, the first amino acid to be attached to Merrifield 
resin was a BOC-amino acid and not Fmoc-amino acid, as triethylamine employed for 
this reaction would effect partial cleavage of Fmoc group. This problem does not arise 
in the case of p-alkoxybenzyl alcohol resin. Consequently, the first amino acid was 
attached by employing Fmoc-amino acid. For the introduction of the final amino acid 
in all these analogues, BOC-amino acid active esters were employed. If Fmoc- 
protection had been employed instead of BOC, there would have been partial 
deprotection during the next stage, i.e., ammonolysis. The general scheme of synthesis 
using p-alkoxybenzyl alcohol resin is outlined below.
 
Fmoc- Leu +HOH2C-C6H4–OCH2-C6H4-Resin 
 DCC and p-dimethylaminopyridine 
 
Fmoc- Leu- OCH2-C6H4 – OCH2-C6H4-Resin 
 1) 55% piperidine in CH2Cl2 
 2) Fmoc-Phe-OTcp (3 equiv.) and 
 HOBt (1 equiv.); 60 min 
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Fmoc-Phe-Leu-OCH2-C6H4-OCH2-C6H4-Resin 
1) 55 % piperidine in CH2Cl2 
2) Fmoc-Gly-OTcp (3 equiv.) and 
HOBt (1 equiv.); 60 min 
 
Fmoc-Gly-Phe-Leu-OCH2-C6H4-OCH2-C6H4-Resin 
1) 55 % piperidine in CH2Cl2 
2) Fmoc-Gly-OTcp (3 equiv.) and HOBt (1 equiv.) 
or 
Fmoc-D-Ala-OTcp (3 equiv.) and HOBt (1 equiv.) 
or 
Fmoc-D-Val-OTcp (3 equiv.) and HOBt (1 equiv.) 
 
Fmoc-Gly-Gly-Phe-Leu-OCH2-C6H4-OCH2-C6H4-Resin 
or 
Fmoc-D-Ala-Gly-Phe-Leu-OCH2-C6H4-OCH2-C6H4-Resin 
or 
Fmoc-D-Val-Gly-Phe-Leu-OCH2-C6H4-OCH2-C6H4-Resin 
1) 55 % piperidine in CH2Cl2 
2) BOC-Tyr-OTcp (3 equiv.) and HOBt (1 equiv.) 
or 
BOC-D-Gly(p-OH-phenyl)-OTcp (3 equiv.) and HOBt (1 equiv.) 
 
BOC-Tyr-Gly-Gly-Phe-Leu-OCH2-C6H4-OCH2-C6H4-Resin  (I) 
or 
BOC-Tyr-D-Ala-Gly-Phe-Leu-OCH2-C6H4-OCH2-C6H4-Resin (II) 
or 
BOC-Tyr-D-Val-Gly-Phe-Leu-OCH2-C6H4-OCH2-C6H4-Resin (III) 
or 
BOC-D-Gly(p-OH-phenyl)-Gly-Gly-Phe-Leu-OCH2-C6H4-OCH2-C6H4-Resin (IV)
or 
BOC-D-Gly(p-OH-phenyl)-D-Ala-Giy-Phe-Leu-OCH2-C6H4-OCH2-C6H4-Resin 
(V) 
or 
BOC-D-Gly(p-OH-phenyl)-D-Val-Gly-Phe-Leu-OCH 2-C6H4-OCH2-C6H4-Resin 
(VI) 
 
When the conventional Merrifield resin was employed, the following modifications 
were made in the general scheme. In the first step, BOC-amino acid was reacted with the 
resin at 90° in the presence of triethylamine and BOC-protection from the product was 
removed by treatment with 1N HCl in glacial acetic acid. The remaining steps were 
virtually the same as in the earlier scheme except that the cheaper diethylamine was used 
for deprotection of Fmoc group instead of the more expensive piperidine. But the 
duration of deprotection extends to nearly 2h. Further, it was observed that 
introduction of D-Ser was incomplete with its Fmoc-active ester/HOBt. Therefore, 
Fmoc-D-Ser in the presence of DCC/HOBt was employed to effect complete reaction. 
The general scheme is outlined below. 
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BOC-Leu/BOC-Nle + ClCH2-C6H4-Resin 
 
NEt3 
 
BOC-Leu-OCH2-C6H4-Resin 
or 
BOC-Nle-OCH2-C6H4-Resin 
1) IN HCl/AcOH 
2) Net3 
3) Fmoc-Phe-OTcp (3 equiv.) and HOBt (1 equiv.) 
 
Fmoc-Phe-Leu-OCH2-C6H4-Resin 
or 
Fmoc-Phe-Nle-OCH2-C6H4-Resin 
 
1) 50% Et2 NH in DMF, 2h 
2) Other steps as in the previous scheme; for duration of 
coupling see experimental 
 
BOC-Tyr-D-Gly (p-OH-phenyl)-Gly-Phe-Leu-OCH2-C6H4-Resin (VII) 
or 
BOC-Tyr-D-Ser-Gly-Phe-Leu-OCH2-C6H4-Resin (VIII) 
or 
BOC-Tyr-D-Phe-Gly-Phe-Leu-OCH2-C6H4-Resin (IX) 
or 
BOC-Tyr-D-Ser-Gly-Phe-Nle-OCH2-C6H4-Resin (X) 
or 
BOC-Tyr-D-Phe-Gly-Phe-Nle-OCH2-C6H4-Resin (XI) 
or 
BOC-Tyr-D-Met-Gly-Phe-Nle-OCH2-C6H4-Resin (XII) 
(D-Ser2 was introduced using 3 equiv. of Fmoc-D-Ser in the presence of DCC (2 
equiv.)/HOBt (1 equiv.) 
The protected pentapeptides were then released from the resins by ammonolysis as 
indicated below. 
 
Peptide Resins (I to XII) 
 
NH3-CH3OH Yield (%) 
 
BOC-Tyr-Gly-Gly-Phe-Leu-NH2 (XIII) 76·4 
BOC-Tyr-D-Ala-Gly-Phe-Leu-NH2 (XIV) 73 
BOC-Tyr-D-Val-Gly-Phe-Leu-NH2 (XV) 75 
BOC-D-Gly-(p-OH-phenyl)-Gly-Gly-Phe-Leu-NH2 (XVI) 68 
BOC-D-Gly(p-OH-phenyl)-D-Ala-Gly-Phe-Leu-NH2 (XVII) 69 
BOC-D-Gly(p-OH-phenyl)-D-Val-Gly-Phe-Leu-NH2 (XVIII) 71 
BOC-Tyr-D-Gly-(p-OH-phenyl)-Gly-Phe-Leu-NH2 (XIX) 48 
BOC-Tyr-D-Ser-Gly-Phe-Leu-NH2 (XX) 62 
BOC-Tyr-D-Phe-Gly-Phe-Leu-NH2 (XXI) 51 
BOC-Tyr-D-Ser-Gly-Phe-Nle-NH2 (XXII) 64 
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BOC-Tyr-D-Phe-Gly-Phe-Nle-NH2                               (XXIII)                              52
BOC-Tyr-D-Met-Gly-Phe-Nle-NH2                                 (XXIV)                              63
(The yields reported are after purification of the crude product). 
 
The BOC group was cleaved from the protected peptides by treatment with either 
trifluoroacetic acid or formic acid. 
 
Peptides (XIII to XVIII) 
1) Trifluoroacetic acid 
2) Amberlite IRA-400 
 Yield (%) 
Tyr-Gly-Gly-Phe-Leu-NH2 (XXV) 70 
Tyr-D-Ala-Gly-Phe-Leu-NH2 (XXVI) 78 
Tyr-D-Val-Gly-Phe-Leu-NH2 (XXVII) 81 
D-Gly(p-OH-phenyl)-Gly-Gly-Phe-Leu-NH2 (XXVIII) 75 
D-Gly(p-OH-phenyl)-D-Ala-Gly-Phe-Leu-NH2 (XXIX) 72 
D-Gly(p-OH-phenyl)-D-Val-Gly-Phe-Leu-NH2 (XXX) 76 
 
Peptides (XIX to XXIV) 
98 % Formic acid-anisole 
Amberlite IRA-400 
 Yield (%) 
Tyr-D-Gly(p-OH-phenyl)-Gly-Phe-Leu-NH2 (XXXI) 81 
Tyr-D-Ser-Gly-Phe-Leu-NH2 (XXXII) 78 
Tyr-D-Phe-Gly-Phe-Leu-NH2 (XXXIII) 82 
Tyr-D-Ser-Gly-Phe-Nle-NH2 (XXXIV) 76 
Tyr-D-Phe-Gly-Phe-Nle-NH2 (XXXV) 81 
Tyr-D-Met-Gly-Phe-Nle-NH2 (XXXVI) 77 
 
The peptides were assayed for their ability to inhibit the electrically induced 
contractions of the guinea pig ileum (Kosterlitz and Watt, 1964), and their activities are 
listed below· 
 
(Bioassays were performed at the Government College of Pharmacy, Bangalore) 
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Discussion 
 
The synthetic experiments reveal that superior yields are obtained when Fmoc group is 
used for N-protection along with p-alkoxybenzyl alcohol resin as solid support; further, 
purification of the final peptides was also easier.
Biological assays prove that replacement of Tyr1 by D-Gly(p-OH-phenyl) residue 
leads to inactive peptides thereby emphasising the precise requirements of this position, 
a conclusion drawn by earlier investigators also (Morley, 1980). Further, in conformity 
with the earlier observation (Morley, 1980) we have found that replacement of Gly2 by 
D-amino acids generally leads to increased activity, the exceptions being peptides 
XXVII and XXXII wherein either the branched amino acid D Val or D-Ser with a side 
chain alcoholic function is present in this position. However, the presence of a phenolic 
hydroxyl in the aromatic side chain does not seem to affect the activity (compare 
activities of XXXI and XXXIII). Though the presence of D-Ser2 in peptide XXXII leads 
to decreased activity, the replacement of Leu5 in this peptide by Nle residue (peptide 
XXXIV) enhances the activity significantly. The most potent analogue prepared by us is 
peptide XXXVI in which Gly2 and Leu5 have been replaced by D-Met and Nle 
respectively. 
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